Evidence map›Paper›PMID 35900607›Full record

Trial reportArchives of osteoporosis2022

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study.

Mei Li, Zhenlin Zhang, Qingyun Xue, Qifu Li, Xiaolan Jin, Jin Dong, Qun Cheng, Li You, Hua Lin, Hai Tang and 11 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of osteoporosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 4 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Development and validation of machine learning models for distal instrumentation-related problems in patients with degenerative lumbar scoliosis based on preoperative CT and MRI.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Association BetweenPharmacogenomics and personalized medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 15 institutions in 1 country.

Mei LiDepartment of Endocrinology, National Health Commission Key Laboratory of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zhenlin ZhangDepartment of Osteoporosis and Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Qingyun XueDepartment of Orthopaedics, Beijing Hospital, National Center of Gerontology, Beijing, China.
Qifu LiDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaolan JinDepartment of Endocrinology, Western Theater Command General Hospital, Chengdu, China.
Jin DongDepartment of Endocrinology, The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China.
Qun ChengDepartment of Osteoporosis and Bone Disease, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
Li YouDepartment of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiao Tong University, 100 Haining Road, Shanghai, China.
Hua LinDepartment of Orthopaedics, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Hai TangDepartment of Orthopedics, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing, China.
Lin ShenDepartment of Integrated of Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Xin GaoDepartment of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ji HuDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Soochow, China.
Aijun ChaoDepartment of Orthopaedics, Tianjin Hospital, Tianjin, China.
Pengqiu LiDepartment of Endocrinology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
Rui ShiDepartment of Orthopedics, West China Hospital, Sichuan University, Chengdu, China.
Shuhui ZhengDepartment of Orthopaedics, Heibei General Hospital, Zhengzhou, China.
Ying ZhangDepartment of Endocrinology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiaojiang XiongDepartment of Orthopedics Joint Disease Area, Chongqing Three Gorges Central Hospital, Chongqing, China.
Wei YuDepartment of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Weibo XiaDepartment of Endocrinology, Key Laboratory of Endocrinology, NHC, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China. xiaweibo8301@163.com.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNShanghai Jiao Tong University · CNBeijing Hospital · CNCapital Medical University · CNChongqing Medical University · CNChongqing Three Gorges Central Hospital · CNHuazhong University of Science and Technology · CNNanjing Drum Tower Hospital · CNShanxi Medical University · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNSichuan University · CNSoochow University · CNThird Affiliated Hospital of Guangzhou Medical University · CNTianjin Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of generic teriparatide in improving BMD at lumbar spine in patients with osteoporosis was similar to that of alendronate. It provided a new choice for osteoporosis treatment in Chinese population.

introductionTo determine whether the efficacy of generic teriparatide is noninferior to alendronate for Chinese postmenopausal women with osteoporosis.

methodsEligible patients were randomly assigned (2:1) in a 48-week, open-label design to receive 20 µg sc daily teriparatide or 70 mg oral weekly alendronate. Primary outcome was percentage change in BMD at the lumbar spine from baseline to 48 weeks and was assessed for non-inferiority. The same outcome was further assessed for superiority as a secondary endpoint.

resultsThree hundred ninety-one and 196 participants were randomly assigned to the teriparatide or alendronate group, of whom 379 and 194 receiving at least one dose of teriparatide and alendronate treatment were eligible for the efficacy analysis. Teriparatide was non-inferior to alendronate for BMD change at lumbar spine (treatment difference: 0.7%, 95% CI: - 0.3 to 1.7%), which excluded the predefined non-inferiority margin of - 1.5%. However, teriparatide was not statistically superior to alendronate in improving BMD at lumbar spine (P = 0.169). At 48 weeks, changes in BMD at total hip were - 1.0% and 2.2% in teriparatide and alendronate group, respectively (P < 0.001). The incidence of new fracture showed no statistical difference between groups (P = 0.128). Serum P1NP and β-CTX levels significantly increased in the teriparatide group and markedly decreased in alendronate group (all P < 0.001 vs baseline). The adverse events (AEs) and serious AEs were more common in the teriparatide group than in the alendronate group, which were mainly teriparatide-related hypercalcemia, elevated alkaline phosphatase or parathyroid hormone, dizziness, and arthralgia.

conclusionsTeriparatide was not inferior to alendronate in increasing BMD at lumbar spine in Chinese postmenopausal women, and they achieved these effects through different mechanisms.

Indexed as

Bone Density Conservation AgentsOsteoporosisOsteoporosis, PostmenopausalAlendronateBone DensityChinaFemaleHumansPostmenopauseProspective StudiesTeriparatideAlendronateBone Density Conservation AgentsTeriparatideAlendronateBone mineral densityBone turnover markersPostmenopausal osteoporosisTeriparatide

Identifiers

PMID35900607
PMCPMC9334369
OpenAlexW4288428974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.